Selventa, Janssen Partner on Immunological Diseases | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Selventa today announced a research agreement with Janssen Research & Development in immunological diseases.

The deal includes the development of disease models to shed information about disease-relevant mechanisms and to identify new drug discovery opportunities, Selventa said. Aside from saying the deal is multi-year the company did not disclose the terms.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.

The San Diego Union-Tribune takes a look at the work to be done in personalized medicine.

An op-ed in the Wall Street Journal calls for the establishment of a patent court staffed by judges and experts with science backgrounds.

In PLOS this week: variants that affect COPD biomarkers, high genetic diversity of Cryptococcus gattii in Brazil, and more.